JMA Opposes Selective Treatment Due To Safety Concerns
This article was originally published in PharmAsia News
Executive Summary
In response to the changes proposed at the Japan Regulatory Reform Council’s meeting on April 17, the JMA reiterated its opposition to selective medical treatment.